User fee reauthorization takes one step forward, one backward

The House passed FDA medical product user fee reauthorization legislation June 8, while a Senate committee markup has been postponed as committee staff work to resolve differences over diagnostics, drug importation, generic drug exclusivity reforms and dietary supplements.

House Democratic leadership tinkered with the FDA Amendments Act (H.R. 7667) after the Energy & Commerce endorsed it. ...